Quotient Sciences Ltd

With trusted scientific insight brought to every programme, Quotient Sciences is a clinical development and manufacturing accelerator helping clients bring molecules to cures, fast. 

We pioneered the integration of CRO/CDMO services with Translational Pharmaceutics®—a disruptive platform that enables greater efficiency in drug development. This unique approach integrates drug product manufacturing and clinical testing to reduce costs, improve decision-making, and accelerate timelines by up to 12 months.

With drug product development, manufacturing, and clinical testing facilities located in both the US and the UK, Quotient Sciences has worked with customers as a trusted CRDMO partner for over 35 years.

Our programme design and delivery process accelerates time-to-market for new therapies without sacrificing product and data quality and control along the way.

Our comprehensive drug product (CDMO) services span a variety of dosage forms across early and late stage development, inclusive of drug product formulation development, clinical trial materials manufacturing, tech transfer, and commercial manufacturing.

We are leaders in technologies for solubility enhancement, modified release, pediatric products, HPAPIs, and oral peptides.

Our clinical pharmacology (CRO) services are focused on early-phase studies, including Phase I studies from first-in-human (FIH) to proof-of-concept (POC), as well as single and multiple ascending dose (SAD/MAD) studies, and regulatory and exploratory clinical studies, including human ADME, TQT, DDI, and bioavailability. The customer experience is crucial for all projects, with expert project managers leading every step from project beginning through to reporting.  

Quotient Sciences Translational Pharmaceutics®

Advance molecules through development by integrating traditionally siloed services

Translational Pharmaceutics® is a proven approach of integrated drug development activities that help you reach milestones as quickly and efficiently as possible. We optimise every step by redefining the interconnected relationship between drug product design, supply, and clinical testing.

Key benefits of Translational Pharmaceutics®:

• Streamlining vendor management
• Better decision-making based on emerging human clinical data
• Timeline acceleration by up to 12 months on average.

Early clinical development

Dedicated to early clinical development, we can help your molecule more efficiently reach first-in-human and proof-of-concept (PoC) milestones.

We are focused on delivering the insight you need by offering end-to-end services to manage every aspect of your early clinical programme.

Our more than 30 years of experience includes more than 1,300 Phase I studies conducted at our clinical units in Miami and Nottingham. We also offer a range of exploratory and regulatory-driven Phase I clinical pharmacology studies for registration and product labelling purposes.

Drug product development and manufacturing

Achieve your molecule’s next milestone with fit-for-phase drug product formulations, backed by trusted data and the expertise you need to navigate the increasing complexity of small molecule and synthetic peptide therapeutics.

Our adaptive approach ensures scalable solutions for your molecule’s development, which apply to preclinical through commercial drug product formulation, manufacturing, and supply.

We streamline the transitions between each development stage to help you bring your drug product to your next milestone efficiently, with no compromises to safety or quality.

Key capabilities include:

• Preformulation assessment & formulation development
• Clinical development and acceleration to proof-of-concept (POC) studies
• Boost of formulation and validation of product performance in humans
• Process development, scale-up, and clinical manufacturing for Phase II/III
• Commercial manufacturing & supply.